Dr. Barter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6301 Executive Blvd
Rockville, MD 20852Phone+1 301-770-4967
Education & Training
- University of Alabama Medical CenterFellowship, Gynecologic Oncology, 1983 - 1985
- Duke University HospitalResidency, Obstetrics and Gynecology, 1979 - 1983
- University of Kentucky College of MedicineResidency, Internal Medicine, 1977 - 1979
- University of Virginia School of MedicineClass of 1977
- Washington and Lee UniversityB.S., Magna Cum Laude, 1973
Certifications & Licensure
- MD State Medical License 1985 - 2026
- VA State Medical License 1985 - 2012
- DC State Medical License 1985 - 2008
- NC State Medical License 1979 - 2002
- AL State Medical License 1983 - 1985
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Top Cancer Doctor Newsweek, 2015
- Top Doctor in the Washington Area Washington Consumers� Checkbook, 2014-2015
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Join now to see all
Clinical Trials
- BP1001-A in Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2022 Aug 19
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 207 citationsBenefits and Costs of Using HPV Testing to Screen for Cervical CancerJeanne S. Mandelblatt, William F. Lawrence, Sharita Mizell Womack, Denise L. Jacobson, Bin Yi
JAMA. 2002-05-08 - 1 citationsTolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, John K Chan, Nicoline Raaschou-Jensen
European Journal of Cancer. 2024-09-01 - 57 citationsPhase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancerScott McMeekin, Don S. Dizon, James F. Barter, Giovanni Scambia, Lyudmila Manzyuk
Gynecologic Oncology. 2015-07-01
Journal Articles
- Comparison of robotic, laparoscopic, and abdominal myomectomy in a community hospitalGobern JM, Rosemeyer CJ, Barter JF, Steren AJ, Journal of the Society of Laparoendoscopic Surgeons, 1/1/2017
- Genetic Counseling and Testing for Hereditary Cancer Risk in Young Adult Women: Facilitating Autonomy and Informed Decision Making is Key, Letter to the EditorBeth N. Peshkin, Susan T. Vadaparampil, Lindsey M. Hoskins, Suzanne M. O'Neill, James F. Barter, Gynecologic Oncol. Rep, 1/1/2015
- Phase III Randomized Trial of Second-line Ixabepilone Versus Paclitaxel or Doxorubicin in Women with Advanced Endometrial CancerMckeekin S, Dizon, D, Barter J, Scambia S, Manzyuk L, Lisanskaya L , Oaknin A, Ringuette S, Mukhopadhyay, Rosenberg J, Vergote I, Gynecol Oncol, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Everolimus Plus Letrozole Treatment of Recurrent Gynecologic CancersMiller K, Min D, Barter J, Hughes C, Kalnitskaya L, Bell-Farrell W, Lalagari S, Solis A, Phelps J, Wade C, Feldman M, ASCO Annual Conference, Chicago, IL, 1/4/2019
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer (OC) Following R...Antonio Gonz�lez Mart�n, Luis Rojas, Patricia Braly, James Barter, David O'Malley, Amit Oza, Ashley Haggerty, Christof Vulsteke, Diane Provencher, Whitney Graybill, Yo..., Chicago, IL, 1/2/2017
- A Chemoresponse Assay for Prediction of Platinum Resistance in Primary Ovarian CancerThomas C. Krivak, Angeles Alvarez Secord, Scott Richard, Charles A. Leath III, Richard G. Moore, Robert L. Coleman, James Fiorica, James Barter, Gordon O. Downey, Chun..., WAGO, Seattle, WA, 1/26/2013
- Join now to see all
Press Mentions
- Dr. James Barter at Advantia Health Achieves New Milestone for Minimally Invasive Laparoscopic SurgeryAugust 8th, 2018
Grant Support
- Thromboxane A2 Inhibitor Canine Intestine RadiationNational Center For Research Resources1988
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: